Form 4: Catalyst Pharma CMO Granted Equity Awards

Catalyst Pharmaceuticals' Chief Medical Officer, William T. Andrews, received new equity awards including stock options and restricted stock units.

Summary

• William T. Andrews, Chief Medical Officer of Catalyst Pharmaceuticals, Inc. (CPRX), was granted new equity awards on November 20, 2025.
• The awards include 98,652 options to purchase common stock with an exercise price of $22.77 per share, expiring on November 20, 2032.
• Additionally, 29,776 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock upon vesting.
• Both the options and RSUs will vest in equal tranches: one-third on November 20, 2026, one-third on November 20, 2027, and the final third on November 20, 2028.
• Following these transactions, Mr. Andrews beneficially owns 238,360 options and 268,136 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is a positive signal for executive retention and alignment with shareholder interests, reflecting standard compensation practices. It doesn't introduce new risks or significant financial changes beyond compensation.

Positives

• The grant of equity awards aligns the Chief Medical Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over three years encourages retention of key management personnel.

Future Outlook

The equity awards, with their multi-year vesting schedule, indicate a long-term commitment to the company's future performance and the retention of key executive talent.

Industry Context

Equity grants to executive officers are a standard practice in the pharmaceutical industry to attract, retain, and incentivize top talent, aligning their compensation with shareholder value creation and long-term strategic goals.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in the biotechnology and pharmaceutical sectors typically include a mix of stock options and restricted stock units, often with multi-year vesting schedules.
• The size and structure of these grants are generally competitive, reflecting the executive's experience, the company's stage of development, and its market capitalization.
• While specific comparable companies or projects are not detailed in this filing, the nature of the grant is consistent with common industry practices for executive compensation.

Stakeholder Impact

• Shareholders: Interests are further aligned with management through equity ownership, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The granted options and Restricted Stock Units will vest in three equal annual tranches starting November 20, 2026.
• Shares of common stock will be delivered to the reporting person upon the vesting of the Restricted Stock Units.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. It does not provide new information that would fundamentally alter the investment thesis for Catalyst Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook rather than this specific disclosure.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, William T. Andrews, Chief Medical Officer